1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 18th March 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Stanford Community Symposium 2018: Phair, Metabolic traps, Tryptophan trap

Discussion in 'ME/CFS research news' started by NelliePledge, Sep 30, 2018.

  1. Trish

    Trish Moderator Staff Member

    Messages:
    51,890
    Location:
    UK
    Thank you Chris Ponting. It's great to have scientists sharing their research findings here.
    With respect to this point:
    This could presumably be interpreted in two ways:

    The biobank data indicate the IDO2 hypothesis is wrong or

    The biobank data not matching the 20 severely ill patient study data for IDO2 indicates that a lot of people are self identifying as having CFS when they don't so the data are too contaminated to conclude anything. Given that specialist clinics indicate that many of the people sent to them with CFS don't actually have it, this could be an important factor.
     
    Sarah94, andypants, Hutan and 10 others like this.
  2. adambeyoncelowe

    adambeyoncelowe Senior Member (Voting Rights)

    Messages:
    2,731
    Could it also relate to differences in how patients are identified in the UK and USA? Potentially, these 20 patients may represent a fluke?
     
    andypants and Inara like this.
  3. alex3619

    alex3619 Senior Member (Voting Rights)

    Messages:
    2,129
    Presuming this is correct, here is another issue. The marker was found from the severe patients study. Supposing its not important for most patients, it might be a marker leading to severity, rather than causative. The biobank will not show this unless the results are stratified for severity. Were they?
     
    andypants, merylg, Hutan and 8 others like this.
  4. alex3619

    alex3619 Senior Member (Voting Rights)

    Messages:
    2,129
    So far as I am aware only Lipkin and his team did this.
     
    andypants, Sly Saint and Barry like this.
  5. alex3619

    alex3619 Senior Member (Voting Rights)

    Messages:
    2,129
    OR, given the situation in the UK, the false diagnosis rate is atrocious.
     
    Sarah94, andypants, Barry and 3 others like this.
  6. Sunshine3

    Sunshine3 Senior Member (Voting Rights)

    Messages:
    622
    It's frightening to think that samples from UK biobank aren't accurate....I'd have assumed they run a tight ship. I wonder what criteria they use?
     
  7. Trish

    Trish Moderator Staff Member

    Messages:
    51,890
    Location:
    UK
    This is about the UK biobank which is a national biobank which has huge numbers of samples from people with lots of different conditions, including some who self identify as having CFS.

    It is completely different from the UK ME/CFS Biobank which is much smaller and very careful about diagnostic criteria since it was specifically set up to study ME by the MEA and others. They are doing some good research studies and providing samples to other researchers.
     
    Robert 1973, Sing, Binkie4 and 13 others like this.
  8. Sunshine3

    Sunshine3 Senior Member (Voting Rights)

    Messages:
    622
    Oh thanks Trish, phew!! I was thinking this sounds like a total dog's dinner!! Thanks for setting me straight.
     
    Binkie4, andypants, MeSci and 2 others like this.
  9. Snowdrop

    Snowdrop Senior Member (Voting Rights)

    Messages:
    2,134
    Location:
    Canada
    Did I miss an explanation for why the UK biobank was used for this as opposed to the ME/cfs biobank UK?
     
    Binkie4, andypants and Barry like this.
  10. Trish

    Trish Moderator Staff Member

    Messages:
    51,890
    Location:
    UK
    We have a thread on it here
    Chris Ponting used data the UK biobank made available and looked at genome information from people who presumably ticked a box asking if they had ME/CFS. He found a gene in women that increased their chance of getting ME/CFS.
     
    Binkie4, andypants, MeSci and 5 others like this.
  11. Snowdrop

    Snowdrop Senior Member (Voting Rights)

    Messages:
    2,134
    Location:
    Canada
    I presume this to mean that if the ME/cfs biobank data was used they'd have to generate such data first? And this would be an added cost?

    Otherwise, I appreciate the response but I'm still kinda in the dark as to why that would be preferable.

    Not that I really understand much about any of this.
     
    Binkie4 and andypants like this.
  12. Andy

    Andy Committee Member

    Messages:
    21,814
    Location:
    Hampshire, UK
    I believe this to be correct, the UK ME/CFS Biobank has not analysed their samples in the same way that they UK Biobank has. It's also a numbers game, even if they had the genome data, currently "the UKMEB now has over 600 people participating in the Biobank project – people with ME/CFS, Multiple Sclerosis and healthy controls", whereas the data that Chris Ponting analysed was "from 194,174 females and 167,020 males". The blog notes that one of the limitations of their analysis is that "Only one genomic region was identified, so a much larger study is required with about 20,000 ME/CFS cases to find more.", numbers that, obviously, the UKMEB is currently unable to provide.
     
  13. Amw66

    Amw66 Senior Member (Voting Rights)

    Messages:
    6,263
    andypants and Barry like this.
  14. Forbin

    Forbin Senior Member (Voting Rights)

    Messages:
    1,581
    Location:
    USA
    I stumbled upon this May 2018 article concerning Tryptophan, the Kynurenine Pathway and IBD (Inflammatory Bowel Disease).

    Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis

    https://academic.oup.com/ibdjournal/article-abstract/24/7/1471/5001501?redirectedFrom=fulltext

    As near as I can tell, the study found that an increase in the ratio of Kynurenic acid to tryptophan was associated with inflammation in uclerative colitis (a form of IBD that seems to show up in some ME patients).

    From what little I know about the metabolic trap, I would guess that you'd see a proportional increase in tryptophan in "the trap," as opposed to kynurenine. On the other hand, I believe in this IBD study they tested the serum as opposed to cell contents. Perhaps a build up of tryptophan in the cells lowers its level in the serum, thus increasing the proportion of kynurenic acid to tryptophan in the serum. Of course, this study's findings may have nothing to do with "the trap."

    The researcher in the video suggests that additional kynurenic acid may be being generated elsewhere, and mentions the microbiome as a possible location.
     
    Last edited: Nov 26, 2018
    Inara, andypants, Andy and 2 others like this.
  15. Londinium

    Londinium Senior Member (Voting Rights)

    Messages:
    270
    Cross-linking to @MeSci's post on Carmine Pariente's latest paper 'Persistent fatigue induced by interferon-alpha: A novel, inflammation-based, proxy model of Chronic Fatigue Syndrome', which notes:

    This would seem to tie in with the prediction made by @RDP as shown on the slide on the very first page of this thread. Interesting...
     
    Inara, andypants, Sly Saint and 6 others like this.
  16. Amw66

    Amw66 Senior Member (Voting Rights)

    Messages:
    6,263
    ScottTriGuy likes this.
  17. aquariusgirl

    aquariusgirl Established Member

    Messages:
    4
    adambeyoncelowe likes this.
  18. alex3619

    alex3619 Senior Member (Voting Rights)

    Messages:
    2,129
    adambeyoncelowe likes this.
  19. FMMM1

    FMMM1 Senior Member (Voting Rights)

    Messages:
    2,596
    Only looked at this for a few minutes but what your saying seems reasonable.

    If IDO1/2 are not working then intracellular tryptophan will increase while intracellular kynurenine will decrease (Phair). It seems reasonable that intracellular Kynurenic acid will also decrease since it is formed after the IDO1/2 stage [https://en.wikipedia.org/wiki/Kynurenine_pathway].

    Fluge/Mella (2016) and Armstrong (2015) showed that amino acids (including tryptophan) were lower in plasma since they were being used as cellular fuel in ME/CFS. So lower plasma levels could indeed reflect higher intracellular levels.

    Maureen Hanson/Norwegian group is doing/has done a study re-setting the microbiome (faecal transplants); don't think it's that easy to re-set the microbiome. Interesting that this group may be highlighting a change to the microbiome resulting in more Kynurenic acid. Wonder if this would give you more kynurenine; bypassing the IDO1/2 stage; an example of nature coming up with a workaround? Wonder if Phair's looked at this study?

    Anyway the reason I'm on here is that I think Phair is interested in another potential metabolic trap i.e. substrate inhibited enzyme (operating at lower substrate levels) and a second enzyme operating at higher substrate levels. Anyone know what this second trap is?
     
    obeat, Barry, AliceLily and 5 others like this.
  20. FMMM1

    FMMM1 Senior Member (Voting Rights)

    Messages:
    2,596
    Just found this by accident. Could someone send me a link to the original data/post.

    I was wondering if someone had checked the genetic data i.e. to see relationship between IDO2 mutation and incidence of ME/CFS. However, understanding even a small percentage of cases may help to explain the disease mechanism more generally.
     
    andypants likes this.

Share This Page